Actively Recruiting

All Genders
NCT06510868

Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

Led by University Health Network, Toronto · Updated on 2026-03-05

45

Participants Needed

1

Research Sites

256 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective observational study which aims to identify individuals predisposed to developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) could improve patient outcomes in different ways. First, it will enable improved patient selection for PRRT where alternative treatment options are available. Second, understanding the final pathway and how it is modulated by PRRT could allow the design of strategies to halt this process. Third, while it is unknown whether the development of MDS and AML is a late effect of radiopharmaceuticals in general or it is confined to cancer populations or specific radioisotopes will need to be confirmed. Finally, understanding this devastating complication is expected to be the cornerstone towards advancing radiopharmaceuticals' role in the adjuvant setting.

CONDITIONS

Official Title

Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • ECOG performance status 0 to 3
  • Life expectancy greater than 6 months
  • Provide informed consent and agree to serial genetic panel CHIP testing
  • Cohort A: Completed PRRT within 5 years before enrollment
  • Cohort B: Planned to start PRRT within 4 months after enrollment
  • Cohort C: Diagnosed with MDS or AML after prior PRRT
Not Eligible

You will not qualify if you...

  • Unwillingness to provide blood samples and attend follow-up as per protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Princess Margaret Cancer Centre

Toronto, Ontario, Canada, M5G 2M9

Actively Recruiting

Loading map...

Research Team

R

Rebecca Wong

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here